Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Nested Therapeutics Announces Oral Presentation of Preclinical Data for NST-628, a Novel, Fully Brain-Penetrant, Pan-RAF/MEK Molecular Glue, at the 2024 AACR Annual Meeting | ||
By: PR Newswire Association LLC. - 08 Apr 2024 | Back to overview list |
|
Concurrent publication in the journal Cancer Discovery highlights NST-628's differentiated mechanism and preclinical activity across diverse KRAS-, NRAS-, and BRAF-driven tumors Phase 1 study of NST-628 open and enrolling patients with advanced solid tumors; Company expects to initiate dosing imminently SAN DIEGO, April 8, 2024 /PRNewswire/ -- Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced that preclinical data for the company's lead program, NST-628, were featured in an oral presentation in the "New Drugs on the Horizon" series at the American Association for Cancer Research (AACR) Annual Meeting. The presentation, titled "NST-628 is a Novel, Potent, Fully Brain-Penetrant MAPK Pathway Molecular Glue that Inhibits RAS- and RAF-Driven Cancers," was given by Klaus Hoeflich, Ph.D., chief scientific officer and co-founder of Nested. The data were published concurrently online in the journal Cancer Discovery. "Dysregulation of RAS-MAPK pathway signaling is one of the most frequently occurring events in tumor development, impacting one in three newly diagnosed patients in the U.S. every year, the vast majority having no approved targeted treatment alternatives. While therapies have been developed for every node of the pathway, tolerability and durability of response continue to be challenging for patients with these difficult-to-treat cancers," said Dr. Hoeflich. "NST-628 was developed as a fully brain-penetrant, non-degrading molecular glue targeting the RAF and MEK nodes of the RAS-MAPK pathway. The preclinical data presented at AACR show that NST-628 induces broad efficacy in tumor models and demonstrated the potential to overcome limitations of existing MEK and RAF inhibitors and RAS inhibitors in development. With a half-life and metabolic profile optimized to achieve a superior therapeutic index on a daily dosing schedule, as well as full intrinsic blood brain barrier penetrance, these data support NST-628's potential as a best-in-class treatment for RAS- and RAF-driven cancers." Preclinical data presented at AACR and published in Cancer Discovery highlight the differentiated mechanism and drug-like properties of NST-628. Specifically:
About the Phase 1 Study of NST-628 About NST-628 About Nested Therapeutics View original content to download multimedia:https://www.prnewswire.com/news-releases/nested-therapeutics-announces-oral-presentation-of-preclinical-data-for-nst-628-a-novel-fully-brain-penetrant-pan-rafmek-molecular-glue-at-the-2024-aacr-annual-meeting-302110793.html SOURCE Nested Therapeutics Inc. |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |